Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.37 |
| ▸ | OXTR | P30559 | 4/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.37 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498353 | 0.88 | BRD4 (0.39) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2495336 | 0.87 | BRD4 (0.41) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2496752 | 0.86 | L3MBTL1 (0.39) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2494027 | 0.86 | AVPR1A (0.44) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL5357275 | 0.85 | AVPR1A (0.51) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2493428 | 0.84 | BRD4 (0.38) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2498096 | 0.83 | BRD4 (0.37) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2495051 | 0.81 | AVPR1A (0.42) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2497606 | 0.81 | AVPR1A (0.36) | BRD4AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL2497539 | 0.80 | AVPR1A (0.38) | BRD4AVPR1AAVPR1BOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | BRD4 822/4885AVPR1A 2/4885AVPR1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.